M. Yacur

Most-cited papers

1. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

   A. Mato, Meghan C. Thompson, J. Allan, D. Brander +44 more

   2018Haematologica155 citations Open access

   Semantic Scholar

   Save

2. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

   A. Mato, B. Hill, N. Lamanna, P. Barr +25 more

   2017Annals of Oncology147 citations Open access

   Semantic Scholar

   Save

3. Diacylglycerol kinase alpha is a critical signaling node and novel therapeutic target in glioblastoma and other cancers

   Charli L Dominguez, D. Floyd, Aizhen Xiao, Garrett R. Mullins +8 more

   2013Cancer Discovery103 citations Open access

   Semantic Scholar

   Save

4. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

   A. Mato, B. Hill, N. Lamanna, P. Barr +25 more

   2017Annals of Oncology67 citations Open access

   Semantic Scholar

   Save

5. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients.

   A. Mato, B. Hill, N. Lamanna, P. Barr +25 more

   2017Annals of Oncology24 citations

   Semantic Scholar

   Save

6. Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients

   A. Mato, N. Lamanna, C. Ujjani, D. Brander +24 more

   201620 citations

   Semantic Scholar

   Save

7. Cryotherapy for Prevention of Chemotherapy Induced Peripheral Neuropathy in Breast Cancer.

   Mihir Tandon, M. Yacur, C. Brenin, Patrick Dillon

   2023Critical reviews in oncology/hematology15 citations

   Semantic Scholar

   Save

8. Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients

   A. Mato, C. Tam, J. Allan, D. Brander +41 more

   201715 citations

   Semantic Scholar

   Save

9. Gender Disparity in Breast Cancer: A Veteran Population-Based Comparison.

   Anita Aggarwal, B. Adepoju, M. Yacur, D. Maron +1 more

   2021Clinical Breast Cancer13 citations

   Semantic Scholar

   Save

10. Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies

    A. Mato, J. Allan, J. Pagel, D. Brander +41 more

    201711 citations

    Semantic Scholar

    Save

11. Do Current Lung Cancer Clinical Trials Represent All Patient Populations Including Minorities?

    Apurva Nemala, A. Ullah, M. Yacur, N. Karim

    2023Clinical Lung Cancer4 citations

    Semantic Scholar

    Save

12. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients

    A. Mato, B. Hill, N. Lamanna, P. Barr +21 more

    20164 citations

    Semantic Scholar

    Save

13. Evaluating the Khorana Score in Advanced EGFRMutated NSCLC Patients Receiving First-Line Osimertinib

    M. Yacur, Najeebah Bade, Shubha V. Srinivas, A. Benyounes

    2025Biomedical Journal of Scientific & Technical Research0 citations Open access

    Semantic Scholar

    Save

14. EP12.01-41 Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib

    A. Benyounes, A. Cohen, S. Rossi, T. Cannon +1 more

    2023Journal of Thoracic Oncology0 citations Open access

    Semantic Scholar

    Save

15. A Unique Case of CSF3R-Mutated Chronic Neutrophilic Leukemia with Thrombocytosis

    P. Tizro, M. Yacur, Min-Ling Liu, V. Nava +1 more

    20200 citations Open access

    Semantic Scholar

    Save

16. Deplete and Delirious: A Report of Two Cases

    Amanda E. Bryson, M. Yacur, Meeta Desai, Eileen F Hennrikus

    20170 citations

    Semantic Scholar

    Save